Comparison of targeted next generation sequencing assays in non-small cell lung cancer patients Authors: Ieva Drejeriene, Jurate Gruode, Saulius Cicenas, Charalambos Loizides, Alexia Eliades, Achilleas Achilleos, Elena Kypri, Kyriakos Tsangaras, Marios Ioannides, George Koumbaris, Diana Stanciute, Arnoldas Krasauskas, Philippos C Patsalis Published: 2024 ABSTRACT AbstractNon-small cell lung cancer (NSCLC) is the most prevalent type of lung cancer the mutational spectrum of which has been extensively characterized. Treatment of patients with NSCLC based on their molecular profile is now part of the standard clinical care. The aim of this study was firstly to investigate two different NGS-based tumor profile genetic tests and secondly to assess the clinical actionability of the mutations and their association with survival and clinicopathological characteristics. Overall, 52 mutations were identified in 31 patients by either one or both assays. The most frequently mutated genes were TP53 (40.4%), KRAS (13.46%) and EGFR (9.62%). TP53 and KRAS mutations were associated with worst overall survival while KRAS was positively correlated with adenocarcinoma. The two methods showed a high concordance for the commonly covered genomic regions (97.14%). Ten mutations were identified in a genomic region exclusively covered by the MEDICOVER Genetics custom tumor profile assay. Likewise, one MET mutation was identified by the Ion Amliseq assay in a genomic region exclusively covered by Ion Amliseq. In conclusion both assays showed highly similar results in the commonly covered genomic areas, however, the MEDICOVER Genetics assay identified additional clinically actionable mutations that can be applied in clinical practice for personalized treatment decision making for patients with NSCLC.Supplementary InformationThe online version contains supplementary material available at 10.1007/s12672-024-01640-7.Keyword: NSCLC, mutational profile, clinical utility, next generation sequencing Introduction Lung cancer is the third leading type of cancer globally with an incidence of 22 cases per 100,000 people annually and has the highest mortality rate [1]. NSCLC accounts for approximately 85% of the lung cancer cases [2]. There is an increasing incidence of lung cancer in women with a more favorable prognosis as compared to NSCLC in men [3]. In addition, female patients with NSCLC have an improved benefit compared to men in regard to their treatment response with EGFR inhibitors versus chemotherapy [4]. Molecular targeted therapies against driver mutations of patients with NSCLC are already improving patients’ survival over traditional chemotherapy. Consequently, molecular testing is now applied as part of routine clinical practise [5]. An essential part of the diagnostic procedure in guiding the appropriate treatment for NSCLC is the molecular characterization of the tumor. A variety of techniques are employed to detect molecular alterations including protein-based methods (immunohistochemistry), fluorescence in situ hybridization (FISH) and chromogenic in situ hybridization (CISH) [6]. Most of these methods predominantly depend on a qualitative assessment and can therefore represent a challenge to standarise [6]. NGS testing has been increasingly applied to clinical practice in recent years and is now recommended by professional guidelines for NSCLC molecular profiling [5, 7]. NGS is a sensitive and sufficiently quick method which can simultaneously identify a large number of driver mutations in oncogenes that are associated with targeted therapy and acquired drug-resistance and has been increasingly applied to clinical practice in recent years [8–10]. Patients with EGFR sensitizing mutations in the tumor can now receive EGFR tyrosine kinase inhibitor (TKI) treatment as a first line therapy [5]. Following TKI treatment, if EGFR resistant mutations are identified (e.g EGFT T790M), then osimertinib treatment is recommended [11, 12]. Likewise patients with BRAF V600E mutated tumors can receive dabrafenib, a BRAF inhibitor and trametinib, a MEK inhibitor as first line therapy [5, 13]. MET exon 14 skipping mutated tumors show sensitivity to capmatinib, a MET inhibitor [5, 14]. Moreover, several genes are now emerging as potential biomarkers to identify novel targeted therapies for patients with NSCLC and serve as inclusion criteria in clinical trials [15]. For example, patients with ERBB2 (HER2) exon 20 mutations show clinical response to pan-HER2 blocking drugs [16]. Likewise, activating mutations in the JAK2 gene are shown to confer sensitivity to both JAK2 inhibitors and anti-PD1 immunotherapy in patients with NSCLC [17]. Multi-gene NGS assays have also enabled the simultaneous analysis of multiple genes from a single tumor. It is now clear that a subset to NSCLC patients carry co-existing driver mutations that could explain the heterogeneity in clinical outcomes upon targeted treatment [18]. The biggest challenge for molecular testing is tissue availability of the patient’s tumor. In many cases the amount of formalin fixed paraffin embedded (FFPE) tumor tissue remaining after pathologists’ analysis is limited. The formalin fixation and paraffin -embedding process reduces DNA quality via fragmentation, cross-linking and chemical modifications that introduce DNA damage [19]. These limitations highlight the importance of selecting the appropriate molecular test that can overcome these challenges by introducing quality control checkpoints to ensure high quality molecular data. In addition, the selection of the most appropriate test is of outmost importance to ensure robust diagnostic power by covering the highest number of clinically actionable mutations. In this study the main objective was the comparison of two different NGS-based tests to investigate their sensitivity and clinical utility in identifying clinically actionable mutations in female patients diagnosed with NSCLC. To this end, we analyzed FFPE tissue samples using two different NGS-based assays: i) Ion AmpliSeq Colon and Lung Cancer Research V2 Panel (Ion Torrent PGM platform), an amplicon-based assay that covers hotspot regions in 22 genes associated with lung and colorectal cancer and ii) MEDICOVER Genetics custom- tumor profile assay, that relies on hybrid capture technology and covers hotspot regions and selected targeted regions in 49 genes primarily associated with NSCLC. Sequencing data were compared between the two methods for the commonly covered genomic regions. Moreover, mutations identified in genomic areas exclusively covered by each method are also reported. The diagnostic yield and clinical utility of each assay as well as correlation of molecular findings with clinicopathological parameters is discussed. Results Experimental strategy and patient characteristics Sections were cut from the FFPE block of the primary tumor tissue biopsy for all 51 patients and were subjected to DNA extraction. For 39 patients, the same DNA sample was analyzed by both assays. For 12 patients, different DNA samples (extracted from different sections of the same FFPE block) were analyzed by only one assay, either the Ion Ampliseq Colon Lung v2 assay or the MEDICOVER Genetics custom tumor profile assay (Fig. 1A, B). Out of 51 patients, 39 patients had samples that met quality control criteria and were subjected to targeted sequencing with the two different assays (Fig. 1C). A total of 12 DNA samples were excluded from analysis by both assays due to low or poor DNA quality. The average age of patients was 60.8 years (±9.2). Out of 39 patients, 38.5% were smokers. Most of the patients were diagnosed with adenocarcinoma (74.3%) and 25.7% of them with squamous cell carcinoma. Five patients (12.8%) were diagnosed with stage IV disease, 35.9% of the patients were diagnosed with stage III, 25.6% with stage II and 25.7% with stage I. Out of 29 adenocarcinoma patients 18 (62%) and out of 10 squamous cell carcinoma 8 (80%) patients had either lymph node or distant metastasis (Table 1). Description of the assays and experimental strategy used. A. List of genes covered in the two assays used for molecular profiling of NSCLC tumor specimens. The IonAmliseq assay covers hotspot regions of 22 genes while the MEDICOVER Genetics custom tumor profile assay covers hotspots and other exonic regions of 49 genes. With red are the genes commonly covered by both assays. B. Venn diagram showing the size of the genomic area covered by both assays as well as their overlapping genomic coverage. C. Experimental strategy followed: FFPE specimens from 51 patients diagnosed with NSCLC were subjected to sectioning. For 39 patients, adequate amount of DNA was extracted from the same set of sections and sent to two labs for subsequent analysis with the Ion Ampliseq and the MEDICOVER assays. For 12 patients DNA derived from different sections of the same FFPE block was sent to the two labs for downstream processing. A total of 39 patients met QC parameters and proceeded to NGS. Available sequencing data were used for concordance analysis and estimation of the molecular profile of each tumor sample Table 1Patient characteristics. Clinical details for the 39 patients subjected to NGS analysisCharacteristicn (%)Age (years) Mean (SD)60,8 (9,2) Median (range)61 (40–78) Non-small cell lung cancer Pathological diagnosis39 (100%) Adenocarcinoma29 (74,3%) Squamous cell carcinoma10 (25,7%)Tumor stage I2 (5,2%) IA1 (2,6%) IB7 (17,9%) IIA5 (12,8%) IIB5 (12,8%) IIIA9 (23,1%) IIIB5 (12,8%) IV5 (12,8%)Adenocarcinoma metastatic status Non-metastatic (early-stage)11 (38%) Metastatic18 (62%Squamous cell carcinoma metastatic status Non-metastatic (early-stage)2 (20%) Metastatic8 (80%)Smoking status Non-smoking24 (61,5%) Smoking15 (38,5%) Patient characteristics. Clinical details for the 39 patients subjected to NGS analysis Concordance analysis Overall 31 patients (79.5%) had mutations identified in their tumor specimens by either assay, 27 of which had mutations identified by both assays (69.23%) (Fig. 2A, B). Concordance analysis was performed on sequencing data generated by both assays as described above for the genomic region commonly covered by both methods using the same DNA samples (originating from the same FFPE sections). This commonly covered region consists of hotspot regions of 18 genes with a total genomic size of 8.6 Kb (Fig. 1A, B). Thirty-four variants in 25 patients were identified by both methods while one extra variant -the KRAS G13C at 5.9% VAF- was identified only by the MEDICOVER tumor profile assay in patient 1 (Table 2). The IonAmpliseq assay failed to detect this variant above the minimum acceptable threshold of 5%, however, it was detected at VAF=3.78%. Hence, concordance between the two assays was estimated at 97.14% (Fig. 2C). The frequencies of the concordant mutations in both assays were highly similar (r2=0.9156, Fig. 2C). Concordance analysis in the commonly covered regions by both assays. A. Frequency of NSCLC tumors with mutations identified by either one or both methods (concordant mutations). B. Venn diagram indicating the number of variants identified by either assay. 34 variants were commonly identified by both assays, while one extra variant was identified by the N MEDICOVER Genetics custom tumor profile assay (the KRAS G13C variant was detect below threshold level at VAF < 5% with the IonAmliseq and thus was excluded). C. Distribution of variant allele frequencies (VAF) for the concordant mutations identified by each assay. D. Variability of mutation detection and VAF for NGS data originating from different sections for the same FFPE biopsy Table 2List of mutations in commonly covered regionsSampleIDGeneAA changeCDS mutationType of alterationCOSMIC IDMEDICOVER (%VAF)Ampliseq (%VAF)FEPE1KRASp.G13Cc.37G > TSNVCOSM5275.90NFFEPE2PIK3CAp.E545Kc.1633G > ASNVCOSM76314.0915.58FEPE2TP53p.G266*C.796G > TSNVCOSM4489142.9843.75FEPE3KRASp.G12Ac.35G > CSNVCOSM52238.7034.92FEPE4KRASp.G12Dc.35G > ASNVCOSM52110.799.23FEPE5TP53p.R280Ic.839G > TSNVCOSM112877.537.98FEPE6TP53p.R273Lc.818G > TSNVCOSM1077912.6910.26FEPE8TP53p.G279Ec.836G > ASNVCOSM4371453.8154.19FEPE10TP53p.A159Pc.475G > CSNVCOSM4383630.0023.29FEPE13TP53p.Y163Cc.488A > GSNVCOSM1080828.8631.33FEPE15KRASp.G12Dc.35G > ASNVCOSM52127.9831.85FEPE16TP53p.H178Tfs* 69c.532delINDELCOSM11149529.9723.54FEPE21PIK3CAp.E545Kc.1633G > ASNVCOSM76329.1731.28FEPE25METp.T10101c.3029C > TSNVCOSM70710099.97FEPE25TP53p.R280Tc.839G > CSNVCOSM1072438.8438.38FEPE29TP53p.R110Lc.329G > TSNVCOSM1071633.7739.66FEPE36EGFRp.L858Rc.2573 T > GSNVCOSM622425.3418.47FEPE36TP53p.A159Vc.476C > TSNVCOSM1114829.7532.86FEPE38TP53p.H214Rc.641A > GSNVCOSM4368742.0252.97FEPE40EGFRp.E746_A750delc.2236_2250delINDELCOSM622511.7311.21FEPE45CTNNB1p.G34Ec.1010G > ASNVCOSM567134.4634.15FEPE45EGFRp.E746_A750delc.2235_2249delINDELCOSM622325.3024.56FEPE45TP53p.I255Fc.763A > TSNVCOSM4365130.8131.90FEPE46TP53p.R337Lc.1010G > TSNVCOSM1141121.1427.24FEPE47EGFRp.L747_753delinsSc.2240_2257delINDELCOSM1237066.9257.19FEPE48KRASp.G12Ac.35G > CSNVCOSM52230.3640.32FEPE48PIK3CAS.T1025 = c.3075C > TSNVCOSM2145128.8328.91FEPE48TP53p.P177 = c.531C > TSNVCOSM4367917.0428.48FEPE48TP53p.E349*c.1045G > TSNVCOSM1077064.6255.11FEPE49METp.T1010Ic.3029C > TSNVCOSM70752.0540.78FEPE49TP53p.V157Fc.469G > TSNVCOSM1067043.0250.04FEPE51TP53p.F212Sfs*3c.635_636delINDELCOSM4416224.2624.76FEPE55TP53p.E285Kc.853G > ASNVCOSM1072279.1862.29FEPE55TP53p.M246Ic.738G > ASNVCOSM4431080.8479.06FEPE57KRASp.G12Dc.35G > ASNVCOSM52131.8129.60 List of mutations in commonly covered regions Data are compared from samples analyzed by both assays and originating from the same DNA sample. NF=not found above VAF≥5% threshold. Intra-tumor variability The processing of DNA samples originating from different sections at different layers of the same patients’ FFPE tissue biopsy block enabled the investigation of intra-tumor heterogeneity. As shown in Fig. 2D, two commonly covered variants, TP53 V227G and BRAF V600E were not identified in all sections tested from the same tumor (Figure 2D, Table S1). Given that the two methods have shown performance similarities, this variability does not necessarily reflect differences in the sensitivity of each method but instead could be a result of the heterogeneity of the tissue biopsy samples with different spatial origin within the primary tumor. However, to conclusively characterize the extend of intra-tumor heterogeneity and investigate its clinical importance a large-scale study is required. Assessment of the molecular profile for NSCLC patients Data from all the regions covered from the two assays combined (including overlapping and exclusively covered regions) were used to assess the mutation profile of these patients. A total of 52 mutations were identified in 31 patients. Sixteen patients (51.6%) had just 1 mutation identified in their tumor biopsy (Figure 3A). The total number of mutations did not show significant correlation with tumor content in the FFPE specimens (Supplemental figure 1A). However, there’s a statistically significant increase allele frequency in FFPE samples with tumor content >70% as compared with FFPE samples with tumor content ≤70% (Supplemental Figure 1b). The most frequent mutations were identified in TP53 (21 patients, 40.4%), KRAS (7 patients, 13.46%), EGFR (5 patients, 9.62%) and PIK3CA (4 patients, 7.7%) (Fig. 3B). Mutations in TP53 were predominantly identified in the DNA binding domain (amino acids 98–292) [20], a region known to harbor the majority of deleterious mutations in this gene (Fig. 4A). KRAS mutations were predominantly localized on codon 12, a widely studied recurrent region in multiple cancer types while 1 mutation was identified in codon 13 (Fig. 4B). All KRAS mutations identified were associated with reduced sensitivity to TKI inhibitors [21]. EGFR mutations were identified in the tyrosine kinase domain (Fig. 4C); four in-frame exon19 deletions and one exon 21 L858R substitution, all known to confer sensitivity to EGFR inhibitors such as gefitinib, afatinib and erlotinib [22]. Mutational profile of NSCLC tumors. A. Diagram depicting all the mutations identified by either both or at least one of the two assays. B. Frequency of mutations per gene identified in all patients Distribution of mutations in the most frequently mutated genes. Lollipop plots showing the distribution of mutations across the coding region of A. TP53 B. KRAS C. EGFR Ten mutation and one variant were identified in regions exclusively covered by only one assay. A MET N375S variant (with no clinical actionability) was identified in patient 42 by the Ion Amliseq assay, while 10 more mutations of clinical significance in STK11, RET, PTEN, GNAS, TP53, BRCA2, PALB2, CHEK2, and PIK3CA were exclusively covered and identified by the MEDICOVER tumor profile assay in 10 patients (Fig. 3A, Table S2). Moreover, oncodriver mutations in BRAF, EGFR, KRAS and exon 10/exon21 PIK3CA were found to be mutually exclusive in this cohort (Table 2, Fig. 3). Comparison of clinical utility In total, 52 unique mutations were identified, 50 mutations with the MEDICOVER tumor profile assay and 40 mutations with the Ion Ampliseq assay (Table 2, Table S1, Table S2). These, mutations were assessed based on i) their clinical utility including their association with sensitivity to an approved therapy, ii) resistance to an approved therapy (contraindicated therapy), iii) association with approved therapies in a different cancer type and iv) their investigation in clinical trials (either for their prognostic or potential therapeutic significance). The MEDICOVER Genetics custom tumor profile assay identified more mutations associated with approved therapy in NSCLC as compared to the Ion Ampliseq (6 versus 5 mutations respectively). In addition, 7 mutations associated with resistance to approved therapy (contra-indicated for use) were identified by the MEDICOVER Genetics assay as compared to 6 mutations with the Ion Ampliseq assay. Furthermore, the MEDICOVER Genetics assay identified 8 mutations associated with approved therapy for a different cancer type compared with 3 mutations identified with the Ion Amlpiseq assay. Thirteen mutations identified by the MEDICOVER assay were included in NCCN guidelines for NSCLC as compared to 11 mutations identified with the Ion Ampliseq assay. Finally, 49 mutations associated with clinical trials were identified by the MEDICOVER Genetics assay compared to 39 mutations identified by the Ion Amliseq assay (Figure 5, Table S3). Analysis of clinical utility of the two assays. The number of genes with mutations associated with sensitivity to approved therapy, resistance, or low sensitivity to therapy (contra-indicated), sensitivity to drugs approved for other cancer types and inclusion in clinical trials is indicated Association of mutations with patient survival and clinicopathological characteristics The prognostic significance with respect to overall survival (OS) of the mutations identified in these patients was explored. Patients were divided in early (stage I-II) and late (III-IV) stage NSCLC with or without mutations in TP53 or KRAS. Although there was no statistically significant difference between the 4 groups, a trend was observed for improved OS in late-stage patients with wild-type KRAS or TP53 (Fig. 6). Due to the limited number of patients in the cohort it was not possible to investigate the prognostic significance of each gene separately. Next, associations of mutations in the 4 most frequently mutated genes with clinicopathological characteristics such as age, histology, smoking status were evaluated. A statistically significant association between KRAS status and histology was observed (p=0.03099). Mutated KRAS was positively correlated with adenocarcinoma as opposed to squamous cell carcinoma (Table 3). However, due to the small size of the patient cohort, the results should be interpreted with caution. Overall survival (OS) in patients with and without mutations in KRAS or TP53 in early (I-II) and late (III-IV) stage NSCLC. Red = Stage I-II/mutated, Green = StageI-II/wild type, blue = stageIII-IV/mutated, purple = stage III-IV/wild type Table 3Association of mutations with clinicopathological parametersCharacteristicsGeneGroupWild typeMutantp. valueAgeTP5340–532(40%)3(60%)0.698354–6511(58%)8(42%) > 657(47%)8(53%)KRAS40–533(60%)2(40%)0.336454–652(10.5%)17(89.5%) > 6512(80%)3(20%)EGFR40–534(80%)1(20%)0.623554–6516(84%)3(16%) > 6514(93%)1(7%)PIK3CA40–534(80%)1(20%)0.0556654–6519(100%)0(0%) > 6512 (80%)3(20%)SmokingTP53Yes8(47%)9(53%)0.6427No12(55%)10(45%)KRASYes15(88%)2(12%)0.368No17(77%)5(23%)EGFRYes15(88%)2(12%6)0.8619No19(86%6)3(14%)PIK3CAYes15(88%)2(12%)0.7857No20(91%)2(9%)HistologyTP53ADC17(59%)12(41%)0.1148SCC3(30%)7(70%)KRASADC22(76%)7(24%)0.03099SCC10(100%)0(0%)EGFRADC25(86%)4(14%)0.7515SCC9(90%)1(10%)PIK3CAADC27(93%)2(7%)0.2675SCC8(80%)2(20%)Bold value indicates the statistically significant association between KRAS status and histology was observed (p=0.03099) Association of mutations with clinicopathological parameters Bold value indicates the statistically significant association between KRAS status and histology was observed (p=0.03099) Discussion The purpose of this study was firstly to compare two different NGS-based tests for their clinical utility in patients with NSCLC and secondly to assess the clinical significance of the mutations identified and their associated with clinicopathological parameters. To this end, we employed two different assays; The Ion Ampliseq Colon Lung v2 assay (22 genes) and the MEDICOVER Genetics custom tumor profile assay (49 genes). We first compared the results of both assays in the commonly covered regions with highly similar results and high concordance of VAF. The MEDICOVER Genetics assay identified one additional mutation in the KRAS gene in this region, a KRAS G13C mutation of high diagnostic significance as it is associated with resistance to TKI EGFR inhibitors [23]. The IonAmpliseq assay failed to detect it above threshold (set at ≥5%) in the same DNA sample, but was detected in lower (VAF=3.78%). There are different possible explanations of what we observed. Even with the same DNA material some form of intra-individual variability is to be expected. Another possible explanation regarding this difference may originate form the different methodology these two assays employed (hybrid capture vs amplicon) and their linearity with regards to the true (unknown) VAF. The discrepancy in this specific variant is due to being marginally over the cutoff in one assay and slightly below cutoff in the other. An essential part of MEDICOVER Genetics capture technology is the design of TACS [24]. These are specifically designed to tolerate the presence of mismatches without compromising hybridisation efficiency and enrichment uniformity. Additionally, TACS capture flanking regions that may not be easily captured with amplicon based assays [25]. Most importantly, they ensure capture of all fragments thus providing a better representation of the complexity of the original DNA in the patient’s tumor. These fundamental differences between the two methods can potentially explain the difference observed in regard to the KRAS G13C mutation VAF represents the proportion of DNA fragments with a specific mutation relative to the total DNA fragments in a sample, and higher VAF values generally indicate a higher tumour burden, which can provide insights into the extent of tumour presence and heterogeneity. The sensitivity of mutation detection methods is influenced by VAF, with higher VAF values making it easier to detect mutations, while lower VAF values may challenge detection sensitivity and increase the risk of false negatives. VAF levels can impact treatment decisions by indicating the significance of mutations in disease progression; high VAF mutations may be more actionable and relevant for targeted therapies, whereas low VAF mutations might require more sensitive assays to monitor and could suggest emerging resistance. Allele frequency in the context of tumour profiling refers to the proportion of DNA fragments carrying a particular mutation relative to the total DNA fragments in the sample. In samples with higher tumour content, the allele frequency of mutations will generally be higher. This is because a larger proportion of the DNA originates from tumour cells, which are more likely to contain the mutations of interest. When the tumour content is high, the higher allele frequency makes it easier to detect mutations, as the signal from the mutation is stronger relative to the non-tumour DNA. Higher allele frequencies in a sample can indicate a higher tumour burden, which might correlate with more aggressive disease. Understanding this can help in predicting how a patient might respond to certain treatments. It highlights why accurately assessing tumour content is crucial for reliable mutation detection and for making informed treatment decisions. This understanding is essential for both clinical practice and research in oncology. Tumor heterogeneity is a challenge in clinical practice using FFPE tissue sections. It is well known that FFPE sections can only provide a snapshot of the tumor’s molecular profile and cannot capture intra-tumor heterogeneity. Molecular heterogeneity is a well-known event in non-small cell lung cancer that can be attributed to different mechanisms related to structural chromosomal instability, somatic mutations, tumor mutational burden and genomic instability [8, 26]. In our results, we evaluated the degree of intra-tumor heterogeneity by analyzing different sets of FFPE sections from the patient’s block by either assay. We observed differences in detection rate and allele frequencies of detectable variants that do not necessarily highlight differences between the two methods but are suggestive of intra-tumor heterogeneity. For example, two commonly covered variants, TP53 V227G in patient 19 and BRAF V600E in patient 11 were not identified in all sections tested from the same tumor whereas, KRAS G12D in patient 26 was identified in varying allelic balance (21.06% versus 8.46%) in different sections (Fig. 2D, Table S1). Due to the comprehensive genomic coverage of the MEDICOVER Genetics custom tumor profile assay, a higher number of mutations were identified as compared to the Ion Amliseq method. The additional mutations identified are clinically actionable mutations with either available approved treatments or ongoing trials that investigate their prognostic and/or therapeutic significance. For example, a PIK3CA V344G mutation was identified in a region covered exclusively by the MEDICOVER Genetics’ assay. This mutation resides in the C2 domain of the membrane-binding region of PI3K p110a and has shown sensitivity to p110a/PIK3CA-specific inhibitor alpelisib, a drug recently approved for the treatment of PIK3CA mutated HER2-negative metastatic breast cancer [27, 28]. Furthermore, mutations identified in BRCA2 and PALB2, genes that play a critical role in the homologous recombination repair (HRR) mechanism, could represent potential therapeutic targets for poly(ADP-ribose) polymerase (PARP) 1, 2, 3 inhibitors such as rucaparib. A phase 2 study is currently investigating rucaparib for the treatment of solid tumors including lung cancer associated with deleterious mutations in HRR genes (NCT04171700) [29]. In addition, a GNAS R844C mutation has been identified by the MEDICOVER Genetics’ assay. This mutation lies within a GTP binding region of the Gnas protein resulting in a loss of the GTPase activity and consequently leading to constitutive downstream pathway [30]. The GNAS R844C is shown to associate with resistance to targeted therapy in colorectal patients treated with vemurafenib, cetuximab and irinotecan combination treatment [31]. The clinical significance of this gene in NSCLC is under investigation [32]. Other mutations identified in genes such as PTEN and STK11 are also under investigation for their significance as potential targets of targeted therapy [29]. Furthermore, associations of NGS findings with OS and clinicopathological characteristics were investigated. KRAS or TP53 mutated NSCLC exhibited worse OS in the late-stage NSCLC. This finding is in agreement with previous studies showing that TP53 and KRAS are correlated with adverse prognosis in NSCLC [33, 34]. KRAS mutated tumors were also correlated with adenocarcinoma in our study. KRAS mutations predominately occur in lung adenocarcinomas with a frequency of 17% and are more rare in squamous cell carcinomas (4%) according with data retrieved from the COSMIC database [35]. The small sample size of this study does not allow for a conclusive association of molecular findings with clinical characteristics and highlights the need for larger validation studies. In conclusion, both assays exhibited similar technical performance both in pre-analytical and post-analytical parameters in the commonly covered genomic areas. However, the more comprehensive coverage of the MEDICOVER Genetics custom tumor profile assay in clinically significant genes remarkably expands the potential for identifying additional clinically actionable mutations. These additional mutations were mostly associated with approved therapies in other cancer types as well as clinical trials. Considering the rapid advancements in the molecular etiology of NSCLC and corresponding advancement in molecularly-targeted therapies, the expanded coverage of the custom-made MEDICOVER Genetics assay could potentially allow a more personalized clinical management for an increased number of patients. Materials and methods Patients The study (No. 158200-13-688-219) has been approved by Vilnius Regional Biomedical Research Ethics Committee (Vilnius, Lithuania). All participants of the study have signed the informed consent to participate before study specific procedures started. Tumor tissue samples were collected at National Cancer Institute (Vilnius, Lithuania) and Vilnius University Hospital Santaros Klinikos (Vilnius, Lithuania). DNA preparation Fresh frozen or FFPE tumor tissue biopsy were collected from each patient. DNA extraction was performed using the Qiagen DNeasy blood and tissue kit and the QIAamp DNA FFPE Tissue Kit (Qiagen) for fresh frozen and FFPE tissue respectively, following the manufacturers’ instructions. Tumor content was evaluated on FFPE specimens as the percentage of tumor cells in the total number of nucleated cells using hematoxylin/eosin staining. Minimum tumor content was 10% and maximum tumor content was 95%. DNA was quantified using a spectrophotometric assay (Cary 60 UV-Vis, Agilent Technologies) for fresh frozen tissue derived DNA and a fluorometric based assay for FFPE tissue-derived DNA (Qubit flex fluorometer, Qubit dsDNA high sensitivity assay, Thermo Scientific). A minimum of 10 ng of DNA and a minimum DNA concentration of 1 ng/μl (as measured by a fluorometric based method for FFPE samples) were used as thresholds for library preparation for both assays. DNA quality was assessed using Agilent D1000 ScreenTape analysis (cat.no. 5067–5582). Ion ampliseq colon and lung cancer research panel library preparation and sequencing Libraries were amplified using Ion AmpliSeq Colon and Lung Cancer Research Panel (Ion Torrent by Life Technologies) which analyzes amplicons in hotspots and target regions of 22 oncogenes (Fig. 1A) covering single nucleotide variants (SNVs) and insertions and deletions (Indels) involved in colon and lung cancers. 10 ng of DNA were amplified using Ion AmpliSeq Library Kit 2.0 (Thermo Fisher Scientific) following the manufacturers’ instructions. The library concentration was quantified with Ion Library TaqMan Quantitation Kit (Thermo Fisher Scientific). Each library was diluted to reach a concentration of 100pM and amplified using emulsion PCR. Sequencing was performed on the Ion PGM (Thermo Fisher Scientific) using the Ion PGM 200 Sequencing Kit (Thermo Fisher Scientific). Sequencing libraries were loaded onto a 316 chip following the manufacturers’ instructions. MEDICOVER Genetics custom tumor profile library preparation and sequencing DNA libraries were prepared from sheared DNA based on previously established protocols [37]. Briefly, blunt ending and 5′ phosphorylation was performed using T4 polymerase and T4 kinase respectively. Following adaptor ligation using T4 Ligase (New England Biolabs, Ipswich, UK), nicks were removed using Bst polymerase (New England Biolabs). Unique barcodes were assigned to all samples in a final PCR reaction using Herculase II Fusion Polymerase (Agilent Technologies, Santa Clara, CA). At each step, products were purified using magnetic beads. DNA enrichment for the genomic regions of interest, was carried out using an in solution- hybridization based method using TACS (TArget Capture Sequences) specifically designed to capture selected loci in the genes of interest. Biotinylated TACS were then immobilized on streptavidin coated magnetic beads for subsequent hybridization with the DNA libraries. Eluted samples were amplified using outer-bound adaptor primers. Enriched DNA libraries were then normalized and subjected to sequencing on an Illumina sequencing platform. The MEDICOVER Genetics tumor profile panel was used for the identification of single nucleotide variants SNVs and indels in hotspot regions and selected targeted genomic loci of 49 genes (Fig. 1A). Bioinformatics and data analysis Sequencing data were de-multiplexed with bcl2fastq (v.2.16.0) and aligned to the human genome build 37 (hg19) to generate alignment (bam) files. Specifically, for each sample, paired-end DNA sequencing reads were processed with cutadapt (v.1.8.1) to remove adapter sequences and poor-quality reads (quality base cutoff 25). Reads with length less than 25bps were also removed from further analysis. The remaining sequences were aligned to the human reference genome build 37 (hg19) using the Burrows-Wheeler alignment algorithm (bwa mem). For the MEDICOVER Genetics custom tumor profile assay duplicate read entries were removed to convert aligned reads to a binary (BAM) file containing uniquely aligned read entries only. Per base allele-specific read-depth information was retrieved from this final BAM file. All samples with a minimum depth of coverage of 250 reads proceeded to variant calling with vardict [38]. For concordance analysis, a list of selected targeted genomic coordinates that were commonly covered by both the Ion Ampliseq method and the MEDICOVER Genetics custom tumor profile assay was used. A threshold for VAF (variant allele frequency) for data generated by either method was set at ≥5%. Analysis was also performed in the genomic regions exclusively covered by either the Ion Ampliseq or the MEDICOVER Genetics custom tumor profile assay. Assessment of somatic/germline status was not assessed as germline DNA was not available for this patient cohort. Assessment of clinical utility Assessment of clinical significance was performed by retrieving information from multiple databases. Specifically, pharmacological information was retrieved from the PharmGKB database which consolidates available data on therapies approved by various regulatory authorities including the Food and drug administration (FDA) and the European Medicines Agency (EMA) [39]. Information on association of genes and clinical trials for the indicated cancer type were retrieved from Clinical.trials.gov, a resource provided by the U.S National Library of Medicine [29]. Statistical analysis Survival analysis was carried out in R, using the Kaplan-Meier estimator (survival package in R) [40]. The G-test (R package DescTools) was used to test association for 2x2 contingency tables, specifically between age group, smoking status and histology findings against mutational findings from selected genes [41]. Supplementary Information Additional file 1: The following are available online at www.mdpi.com/xxx/s1, Table S1: List of mutations in commonly covered regions from the analysis performed in different sections of the same FFPE block title, Table S2: List of mutations identified that are exclusively covered by either assay, Table S3: Level of clinical utility for all mutations identified in NSCLC patients. Acknowledgements The authors are indebted to patients and their families for their trust and participation in the present registry. The authors wish to thank Chrysovalanto Marinou, Louisa Constantinou, Charalambos Kkoufou for their laboratory assistance. Institutional Review Board Statement The study (No. 158200-13-688-219) has been approved by Vilnius Regional Biomedical Research Ethics Committee (Vilnius, Lithuania). All participants of the study have signed the informed consent to participate before study specific procedures started. Tumor tissue samples were collected at National Cancer Institute (Vilnius, Lithuania) and Vilnius University Hospital Santaros Klinikos (Vilnius, Lithuania). The study was conducted according to the guidelines of the Declaration of Helsinki. Informed consent was obtained from all subjects involved in the study. Author contributions Conceptualization, PCP, JG, GK methodology ID, AE, KT formal analysis ID, AA, CL, AE; in-vestigation, AE resources, PCP, GK, JG data curation, ID, AA, CL, AK, DS writing—original draft preparation, ID, JG writing—review and editing, AE, MI, CL, AA, DS supervision, GK, AE, EK, MI, SC project administration, AK funding acquisition, PCP Funding This research received no external funding. Data availability The data presented in this study are available on request from the corresponding author. Declarations Competing interests CL: Employed by MEDICOVER Genetics has filed a PCT patent application for Target-enriched multiplexed parallel analysis for assessment of tumor biomarkers (WO2019/008172A1); AA: Employed by MEDICOVER Genetics; has filed a PCT patent application for the Target-enriched multiplexed parallel analysis for assessment of tumor biomarkers (WO2019/008172A1); has filed a PCT patent application for the Enrichment of Targeted Genomic Regions for Multiplexed Par-allel Analysis (WO2019/008148A9); EK: Employed by MEDICOVER Genetics; has filed a PCT pa-tent application for the Target-enriched multiplexed parallel analysis for assessment of tumor biomarkers (WO2019/008172A1); has filed a PCT patent application for the Enrichment of Tar-geted Genomic Regions for Multiplexed Parallel Analysis (WO2019/008148A9); KT: Employed by MEDICOVER Genetics, has filed a PCT patent application for the Enrichment of Targeted Ge-nomic Regions for Multiplexed Parallel Analysis (WO2019/008148A9); AE: Employed by MEDI-COVER Genetics; has filed a PCT patent application for the Target-enriched multiplexed parallel analysis for assessment of tumor biomarkers (WO2019/008172A1); MI: Employed by MEDICOV-ER Genetics; has filed a PCT patent application for the Target-enriched multiplexed parallel analysis for assessment of tumor biomarkers (WO2019/008172A1), has filed a PCT patent applica-tion for the Enrichment of Targeted Genomic Regions for Multiplexed Parallel Analysis (WO2019/008148A9); GK: Employed by MEDICOVER Genetics; has filed a PCT patent application for the Target-enriched multiplexed parallel analysis for assessment of tumor biomarkers (WO2019/008172A1); has filed a PCT patent application for the Enrichment of Targeted Genomic Regions for Multiplexed Parallel Analysis (WO2019/008148A9); PCP: Employed by MEDICOVER Genetics; has filed a PCT patent application for the Target-enriched multiplexed parallel analysis for assessment of tumor biomarkers (WO2019/008172A1); has filed a PCT patent application for the Enrichment of Targeted Genomic Regions for Multiplexed Parallel Analysis (WO2019/008148A9); The rest of the authors declare no conflict of interest. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Ieva Drejeriene, Email: ieva.drejeriene@kulig.lt. Alexia Eliades, Email: alexia.eliades@medicover.com. Philippos C. Patsalis, Email: philippos.patsalis@medicover.com References Associated Data Supplementary Materials Additional file 1: The following are available online at www.mdpi.com/xxx/s1, Table S1: List of mutations in commonly covered regions from the analysis performed in different sections of the same FFPE block title, Table S2: List of mutations identified that are exclusively covered by either assay, Table S3: Level of clinical utility for all mutations identified in NSCLC patients. Data Availability Statement The data presented in this study are available on request from the corresponding author.